Tumor hypoxia, mostly resulting from poor perfusion and anemia, is one of the key factors in inducing the development of cell clones with an aggressive and treatment-resistant phenotype that leads to rapid progression and poor prognosis. Studies in patients with solid tumors suggest that there is a range of hemoglobin (Hb) concentrations that is optimum for tumor oxygenation. When used to achieve an Hb level within this range, erythropoiesis-stimulating agents (ESAs) can be expected to increase tumor oxygenation, and this may favorably influence sensitivity to treatment as well as quality of 
Introduction
For many years, and perhaps among radiation oncologists in particular, it has been widely considered that improving tumor oxygenation is likely to increase sensitivity to treatment. In this context, erythropoiesis-stimulating agents (ESAs) were thought to have a potentially valuable role. Recent concern that ESAs, albeit when used for purposes that are not currently indicated, may adversely affect survival has led us to review their role [1, 2] . It is therefore helpful to look once again at the relationship between tumor oxygenation and pathophysiology. It appears that, while ESAs can have a valuable role in correcting anemia within the indicated range, their use to increase hemoglobin (Hb) levels beyond the recommended target of 12 g/dl has no further benefit and may indeed have adverse effects on tumor oxygenation and response to therapy. In this context, more is not necessarily better.
Hb Level and Oxygenation in Solid Tumors
Several groups have investigated the relationship between tissue oxygen tension distributions in solid tumors and Hb concentration. In cancers of the head and neck prior to treatment, Becker and colleagues found that the median partial pressure of oxygen (pO 2 ) in the tumor rose as the Hb concentration increased from 10 to 14 g/dl, but then fell once the Hb level reached 15 g/dl (Fig. 1A) [3] . We found a similar relationship in patients with squamous cancers of the uterine cervix: tumor pO 2 peaked at an Hb level of 12-13 g/dl and then declined at concentrations above this value (Fig. 1B) [4] .
These findings were surprising given what is known about the relationship between oxygenation status and Hb concentration in healthy tissues. In the normal breast, the median pO 2 remains relatively constant over the range of Hb levels of 8-15 g/dl [5] . In breast cancer, however, the median pO 2 
falls
The Oncologist ® steadily as Hb decreases over this range (Fig. 2) [5] . In malignant tissue, pO 2 is consistently lower than that in healthy tissue at all Hb values, and tumors are invariably hypoxic, with a median pO 2 of <10 mmHg when Hb is <13 g/dl.
It is likely that several factors contribute to tumor hypoxia. The abnormal structure and function of the tumor microvasculature will reduce perfusion, increase the amount of fluid leaking into the extravascular space of the tumor, and thus increase the viscous resistance to flow. Reduced tumor blood flow increases the hypoxic tissue fraction, especially at lower Hb concentrations. Thus, anemia arising as a result of the malignant process itself or of anticancer treatment will play a pivotal part in worsening tumor oxygenation.
The relationship between Hb level and pO 2 assumes importance given the evidence that tumor hypoxia is an independent prognostic factor associated with poor survival. This has been demonstrated, for example, in patients treated for cervical cancer [6] . Among 48 patients whose median pO 2 was <10 mmHg, <40% were alive at 3 years; among 89 patients with a higher median pO 2 , the survival rate at 3 years approached 80% (Fig. 3) [6] . Tumor hypoxia has two sides to it (Fig. 4A ) [7] . On the one hand, tissue O 2 concentrations <1% (pO 2 <7 mmHg) can exert antiproliferative effects: They can restrict cell proliferation, may promote differentiation, and may induce apoptosis and necrosis (Fig. 4A, B) [8] . On the other hand, there are clones within the tumor that react to hypoxic stress with adaptive processes that, through modification of gene expression, confer an aggressive phenotype, promoting local and distant spread (Fig. 4A, B ) [8] [9] [10] [11] [12] .
Hypoxia also promotes angiogenesis, which involves the formation of new blood vessels from pre-existing blood vessels [13, 14] . Generally, tumors are unable to grow beyond a diameter of approximately 1 mm because of an inadequate microenvironment and the resultant lack of essential nutrients and O 2 [14] . For the tumor to increase in diameter, the vascularization must correspondingly increase [13] . Inadequate O 2 supply can result in hypoxia (pO 2 <7 mmHg), which can stimulate angiogenesis through various growth factors [14] [15] [16] [17] . Growth factors such as vascular endothelial growth factor, platelet-derived growth factor-B, transforming growth factor β, insulin-like growth factor-2, and epidermal growth factor are upregulated, whereas angiogenesis inhibitors (i.e., angiostatin, endostatin, 16 kDa protactin, leukemia inhibitory factor) can be shut down [13, 14, [18] [19] [20] [21] [22] . However, the vessels formed in this process are not the same as those found in normal tissue. These newly formed tumor blood vessels are irregularly shaped, have gaps between endothelial cells allowing leakiness, have an incomplete hierarchical structure, and have functional abnormalities [14, 15, 23, 24] . Antiangiogenic drugs may add benefit to cancer treatment, most probably by "normalizing" tumor vasculature.
Many of the changes observed in hypoxia are regulated by hypoxia-inducible factor 1 (HIF-1) (Fig. 4B) [14, 25] . HIF-1α is a transcription factor that regulates the expres- The Oncologist ® sion of >30 target genes involved in hypoxia-induced erythropoietin expression, tumor progression, and tumor aggressiveness [14, 26, 27] . Again, these changes in gene expression and proteomic changes occur at O 2 levels <1%, or <7 mmHg. Hypoxia may also facilitate metastasis, through downregulation of adhesion molecules [14, 28] . The tumor becomes rapidly progressive and acquires resistance to treatment with either chemo-or radiotherapy.
What Happens at Tissue O 2 Concentrations <0.1% (pO 2 <0.7 mmHg)?
Severe hypoxia induces genomic instability and increased selection pressure (Fig. 5A) [14] . Genomic changes and clonal selection occur at O 2 levels <0.1%, or <0.7 mmHg (Fig. 5B) [14, 29] . The aggressive phenotype that results can be considered as a desperate attempt of cancer cells to survive the hostile and nutrient-deprived microenvironment that leads to faster tumor progression that further enhances hypoxia and thus perpetuates this vicious circle.
While the great majority of tumor cells suffer adverse consequences under hypoxic conditions, a small fraction (perhaps <5%) behave quite differently, and selection pressure may favor this minority of cells that can determine the fate of the patient.
Anemic Patients
In anemic patients, hypoxia is more pronounced [30] . Increases in the Hb level can be expected to have a favorable effect on prognosis only when they result in better tumor oxygenation. This is unlikely to be the case when Hb concentrations rise to >14 g/dl. At this level, it is anticipated that the rise in viscosity and resistance to flow within the chaotic microvasculature of the tumor will lead to a net reduction in O 2 supply.
Implications for the Use of ESAs
It is in this context that the use of ESAs must be considered. In a study by Henke et al. [1] , which has attracted considerable attention, epoetin beta was used off-label in head and neck cancer patients being treated with radiation, with the aim of achieving radiosensitization by increasing Hb levels to 14 g/dl in women and 15 g/dl in men. These targets were achieved in 82% of patients treated with epoetin and in 15% of controls (Fig. 6A) [1] . However, there was also a negative impact on progression-free and overall survival times. The likely reason is that the starting level of Hb was inappropriately high (median baseline values were 11.7 g/dl in the epoetin group and 11.8 g/dl among placebo patients), as was the ultimate target of ESA therapy. Against this background, the use of epoetin can be regarded as overtreatment that resulted in Hb levels beyond the optimum range for tumor oxygenation suggested by the work (mentioned above) of Becker et al. [3] and Vaupel et al. [4] (Fig. 6B) [1, 3, 4, 31] . Many placebo patients, in contrast, have had Hb levels that were within the optimum range.
In the case of the BEST study in breast cancer (Breast Cancer Erythropoietin Survival Trial), treatment with epoetin was begun if the Hb level was ≤13 g/dl at baseline [2] . It is likely that the poorer survival seen in this trial among patients given the ESA was again related to the high Hb level that resulted. Such off-label studies should not undermine the use of ESAs within the clearly defined clinical settings in which trials have demonstrated their benefit. A value of 12 g/dl is an appropriate Hb concentration to use as the target of ESA therapy, not as its starting point. The range 12-14 g/dl can perhaps represent the upper range that may still be tolerated. Levels >14 g/dl should be avoided.
It should also be noted that the alternative to the use of ESAs, that is, blood transfusions, leads to large fluctuations in Hb level in which the troughs clearly lie below the optimum range for tumor oxygenation (Fig. 7A) [32] . This www.TheOncologist.com contrasts with the use of ESAs that achieve, through steady increments, an Hb level consistently within the optimum range (Fig. 7B) [33] . Cyclic hypoxia, of the kind that results from repeated RBC transfusions, is also believed to strongly promote an aggressive tumor phenotype [34] [35] [36] .
Conclusion
Only increases in Hb levels that result in improvements in tumor oxygenation can be expected to have a favorable effect on prognosis. At higher Hb levels (>14 g/dl), a substantial rise in the viscous resistance to flow within the chaotic tumor microvasculature can be expected and may lead to a net reduction in O 2 supply, and thus poor tumor oxygenation. Only increases up to the currently recommended target Hb levels result in improvements in tumor oxygenation, and thus may improve prognosis. ESAs should be used as indicated and within the current European Organization for Research and Treatment of Cancer guidelines to achieve the optimum Hb levels [37] . 
